Naslov
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease- modifying therapies: A multicenter, case-control study
(Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high- efficacy disease-modifying therapies: A multicenter, case-control study)

Autori
Habek, Mario ; Jakob Brecl, Gregor ; Bašić Kes, Vanja ; Rogić, Dunja ; Barun, Barbara ; Gabelić, Tereza ; Emeršič, Andreja ; Horvat Ledinek, Alenka ; Grbić, Nevena ; Lapić, Ivana ; Šegulja, Dragana ; Đurić, Koraljka ; Adamec, Ivan ; Krbot Skorić, Magdalena

Izvornik
Journal of neuroimmunology (0165-5728) 359 (2021); 577696, 5

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
multiple sclerosis ; COVID-19 ; disease modifying therapy ; SARS-CoV-2 IgG antibody

Sažetak
Aim To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). Methods Seventy-four pwMS taking high- efficacy DMTs (specifically natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine and ublituximab) and diagnosed with COVID-19 and 44 healthy persons (HC) were enrolled. SARS-CoV2 antibodies were tested with Elecsys® Anti-SARSCoV- 2 S assay. Results pwMS taking high-efficacy DMTs had a significantly higher chance of having negative titer of SARS- CoV2 antibodies compared to healthy controls (33 negative pwMS [44.6%] compared to one negative HC [2.3%], p < 0.001). pwMS taking B-cell depleting therapy (ocrelizumab and ublituximab) had a significantly higher chance of having negative titer of SARS-CoV2 antibodies compared to pwMS on all other DMTs (29 negative pwMS on B-cell therapy [64.4%] compared to four negative pwMS on all other DMTs [13.8%], p < 0.001). Out of other DMTs, two (33.3%) pwMS taking fingolimod and two (16.7%) pwMS taking cladribine failed to develop IgG SARS- COV-2 antibodies. B- cell depleting therapy independently predicted negative titer of IgG SARS-CoV-2 antibody (Exp[B] =0.014, 95%CI 0.002– 0.110, p < 0.001). Conclusions A significant proportion of convalescent COVID-19 pwMS on high-efficacy DMTs will not develop IgG SARS-CoV-2 antibodies. B-cell depleting therapies independently predict negative and low titer of IgG SARS-CoV-2 antibody.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA